BioCentury
ARTICLE | Distillery Therapeutics

Inhibiting BAHCC1 for melanoma

January 2, 2024 11:52 PM UTC

Inhibiting the activity of BAHCC1, a transcriptional regulator of cell-cycle progression and DNA repair whose expression is driven by oncogenic super-enhancers, could help treat melanoma by decreasing tumor growth and increasing PARP inhibitor sensitivity. 

Chromatin immunoprecipitation sequencing of human melanoma cell lines and a human normal skin cell line showed a melanoma-specific super enhancer localized to the BAHCC1 promoter. ...

BCIQ Company Profiles

University of Strasbourg